New ‘Drug Factory’ Implant Eliminates Mesothelioma in Mice

New ‘Drug Factory’ Implant Eliminates Mesothelioma in Mice

A new ‘drug factory’ implant has eliminated advanced-stage mesothelioma tumors in mice. The treatment is effective in just a few days. It works by combining a “drug factory” implant with a checkpoint inhibitor drug. The news comes from researchers at Rice University and Baylor College of Medicine. The treatment worked in 100% of the animals treated. And it shows amazing hope for the future of mesothelioma. How the Treatment Works The treatment uses tiny drug-producing beads no larger than the tip of a needle. The beads go to work next to the mesothelioma tumor. Here, they work to produce continuous, high doses of interleukin-2 (IL-2). IL-2 is a natural compound that triggers white blood cells to fight cancer. The study … Continue reading New ‘Drug Factory’ Implant Eliminates Mesothelioma in Mice »

The RARECARE Project: An International Network Includes Mesothelioma

The RARECARE Project: An International Network Includes Mesothelioma

The RARECARE Project is a network of international clinicians who support rare tumor patients. This includes malignant mesothelioma, the asbestos-caused cancer. RARECARE wants to ensure access to clinical trials. And to the second opinion of cancer specialists. They are working towards guaranteeing equal health care access and better care management. Humble Beginnings In 2008, the European Commission started the RARECARE project. It is a cancer registry with patient data. They are trying to define the incidence, prevalence, and outcome of rare cancers. Soon, the RARECARE registry led to a second project, RARECAREnet. This updated and enlarged the available information on rare cancers in Europe. Mesothelioma remains one of the rarest of rare cancers. It is more common in the UK … Continue reading The RARECARE Project: An International Network Includes Mesothelioma »

Localized Mesothelioma Successfully Treated with Chemotherapy and Surgery

A patient with a rare, localized malignant pleural mesothelioma has been successfully treated. The patient received chemotherapy and surgery and has been disease-free for 12 months. Many believe that a localized form of pleural mesothelioma might have a better survival outlook. This is compared with patients who have the more common, diffuse variety. This latest report comes from a Japanese team of thoracic surgeons. Local vs. Diffuse Mesothelioma Malignant mesothelioma is a rare cancer affecting an estimated 2,500 Americans annually. All forms of mesothelioma have been linked to asbestos exposure. Malignant pleural mesothelioma is the most common form of malignant mesothelioma. Most pleural mesothelioma patients have a type of cancer that tends to spread quickly. It spreds across the thin membrane … Continue reading Localized Mesothelioma Successfully Treated with Chemotherapy and Surgery »

Mesothelioma Multidisciplinary Team Improves Patient Outcomes

Localized Mesothelioma Successfully Treated with Chemotherapy and Surgery

Oxford University Hospital found that a multidisciplinary team is best in mesothelioma care. This treatment approach includes many doctors who are experts in different specialties. Together, they offer the best clinical decision-making team, and they improve patient outcomes. There are many factors that impact clinical decision-making. But this new report focuses on which factors improve mesothelioma patient care. And which factors support informed decisions about follow-up care. Results showed that the most important factor is a strong team of doctors. Two Heads are Better than One Malignant pleural mesothelioma is a rare, incurable cancer coming from asbestos exposure. Patients have a poor prognosis and a median survival rate of 8 to 14 months. Differences in mesothelioma clinical decision-making are common. … Continue reading Mesothelioma Multidisciplinary Team Improves Patient Outcomes »

New Self-Administered Inhaled Gene Therapy Linked to Mesothelioma Survival

A team of doctors in Japan have developed a new oral inhaled gene therapy for the treatment of mesothelioma. This is a new gene therapy that mesothelioma patients can self-administer, much like an asthma inhaler. There’s new evidence that therapies that prevent cancer cells from forming new blood vessels may offer a better way to approach malignant pleural mesothelioma. Gene therapy has attracted attention in recent years. A new study suggests that inhalable gene drugs are effective treatments for asbestos-induced malignant pleural mesothelioma. Gene Therapy Treatments Mesothelioma is the most deadly of several diseases caused by asbestos exposure, including lung cancer and asbestosis. Most people who develop mesothelioma live less than a year after diagnosis. It is most common in … Continue reading New Self-Administered Inhaled Gene Therapy Linked to Mesothelioma Survival »

Genomic Experts Report Most Complete Picture of Mesothelioma to Date

Genomic Experts Report Most Complete Picture of Mesothelioma to Date

Australian and American genomic experts have completed a key step in improving the treatment of pleural mesothelioma. A new study gives results from a large study of malignant pleural mesothelioma Pleural mesothelioma is a type of cancer that develops on the thin layer of tissue that covers the lungs and chest wall. Asbestos causes mesothelioma and other asbestos-related diseases. Asbestos was used in thousands of industrial, commercial, construction, automotive, and consumer products. Pleural mesothelioma occurs in about 2,000 people in the United States every year. Scientists at the National Centre for Asbestos-Related Disease have taken a dramatic leap forward in the understanding of pleural mesothelioma. DNA Genes Impact Personalized Treatment Plans Previous genomic studies of malignant pleural mesothelioma were limited. … Continue reading Genomic Experts Report Most Complete Picture of Mesothelioma to Date »

Combining Cytology and Immunology for a Less Invasive Mesothelioma Diagnosis

Combining Cytology and Immunology for a Less Invasive Mesothelioma Diagnosis

An invasive surgical or tissue biopsy is often required to get a definitive mesothelioma diagnosis. But a new hybrid exam might offer an alternative for mesothelioma patients. It involves the combination of cytology and immunology. Cytology tests look at the cells in body fluids. It is the analysis of a patient’s cells under a microscope. And immunology is the study of the immune system. Together, these two areas of science provide new hope for mesothelioma patients. The Tokyo Medical University in Japan has been looking into advanced diagnostic options. They believe that a combination of cytology and immunology methods can lead to a definitive diagnosis. This is good news for mesothelioma patients. It will mean a quicker mesothelioma diagnosis without … Continue reading Combining Cytology and Immunology for a Less Invasive Mesothelioma Diagnosis »

New Advancements in Personalized Medicine for Mesothelioma

New Advancements in Personalized Medicine for Mesothelioma

Genomics is a new branch of medicine that involves using a patient’s genetic information to create personalized treatment. New research has begun looking at genetic personalized medicine for mesothelioma. Students from the University of Montana are developing personalized medicine for mesothelioma. Personalized Medicine and Mesothelioma Treatment Mesothelioma is a rare rare and aggressive cancer often caused by asbestos exposure. Environmental exposure to asbestos often causes a higher incidence of malignant mesothelioma. There are approximately 2,000 cases of mesothelioma diagnosed in the U.S. every year. Current standard of care involves a multi-targeted drug combination of Pemetrexid and Cisplatin. This is the only FDA approved chemotherapy for mesothelioma. Chemotherapy is a group of toxic drugs that kill mesothelioma cells by damaging their … Continue reading New Advancements in Personalized Medicine for Mesothelioma »

Electronic Health Record Supports Malignant Pleural Mesothelioma Research

Electronic Health Record Supports Malignant Pleural Mesothelioma Research

A new method of research is becoming more popular in the study of malignant pleural mesothelioma. Most doctors use an electronic health record (EHR) to track patients and their care. Researchers are now using de-identified data from EHR databases to study mesothelioma. Dr. Wheatley-Price’s team encourages the use of real-word evidence to support treatment choices in malignant pleural mesothelioma. How the Database is Built The electronic health record (EHR) has been in use since the 1960s. Some may call it the electronic medical record (EMR). The large majority of hospitals and clinics now use an EHR system to track patients. There are many different types of EHR systems available. The original purpose of the EHR was to allow a third … Continue reading Electronic Health Record Supports Malignant Pleural Mesothelioma Research »

Second Treatment Course May Increase Mesothelioma Patient Survival

Second Treatment Course May Increase Mesothelioma Patient Survival

Oncologists report that a second treatment course may be a good option for some mesothelioma patients. Almost all mesothelioma patients experience progression after the first treatment. Recommendations for a second treatment are still unclear. There is very limited information available on second and repeat treatments. Pemetrexed combined with platinum-based chemotherapy is a standard first treatment for mesothelioma. A report in BMC Cancer says that a repeat treatment may be good for eligible patients. In this study, patients who received a second treatment of chemotherapy survived longer. Understanding Second Treatments or Retreatments Malignant pleural mesothelioma is a rare, aggressive cancer linked to asbestos exposure. There have been several recent treatment advances. But the mesothelioma prognosis is still poor with an average … Continue reading Second Treatment Course May Increase Mesothelioma Patient Survival »

Get your free copy of
“Surviving Mesothelioma” Today!